期刊
DIAGNOSTICS
卷 13, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics13030416
关键词
TDP-43; biomarker; ALS; diagnosis
A systematic review and meta-analysis were conducted to evaluate the diagnostic performance of TDP-43 as a biomarker for ALS. The results showed that CSF TDP-43 levels are higher in ALS patients compared with control groups. CSF TDP-43 could potentially serve as a biomarker for ALS, but more research is needed before definitive conclusions can be drawn.
Background: TAR DNA-binding protein 43 (TDP-43) aggregation in neuronal cells is recognized as a hallmark of amyotrophic lateral sclerosis (ALS). Although the literature strongly supports the pathogenetic role of TDP-43 in ALS pathogenesis, the role of TDP-43 as a biomarker of ALS is controversial. We performed a systematic review and meta-analysis to assess the diagnostic performance of TDP-43 for ALS. Methods: Relevant publications were identified by a systematic literature search on PubMed and Web of Science from their inception to 8 April 2022. Results: Seven studies, including 472 individuals, of whom 254 had ALS according to the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, met the inclusion criteria for our meta-analysis. According to the random-effects model, CSF TDP-43 levels are higher in ALS patients compared with control groups. Conclusions: CSF TDP-43 could represent a biomarker of ALS, but further studies are mandatory before drawing conclusions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据